Illumina Stock Gains Amid Report of New Bid from Roche | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Illumina's stock rose as much as 9 percent today following a report that the San Diego-based genetic analysis tools firm and Roche may have agreed to a deal for Roche to acquire Illumina for $66 per share, or approximately $8.14 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.